Swimming Athlete Suspended for the Presence of Methylphenidate
Ottawa – August 2, 2022 – The Canadian Centre for Ethics in Sport (CCES) announced today that Tayden De Pol, a swimming athlete, received a one-month sanction for an anti-doping rule violation stemming from two separate sample collection sessions. The athlete’s urine samples, collected in competition on March 25, 2022, and April 6, 2022, both revealed the presence of methylphenidate, a prohibited substance. The prohibited substance was consumed by the athlete in a prescription medication for which a therapeutic use exemption (TUE) had not yet been granted by the CCES. The CCES has since granted the athlete a TUE for use of methylphenidate.
Methylphenidate is classified as a “specified substance” on the World Anti-Doping Agency Prohibited List. Under the rules of the Canadian Anti-Doping Program (CADP), an athlete facing a first violation involving a specified substance may be entitled to a sanction reduction based on an assessment of their degree of fault. In this case, the CCES proposed a reduced sanction from the standard sanction of two (2) years of ineligibility to a one-month period of ineligibility.
In response to the CCES’s notification of the adverse analytical finding, Mr. De Pol waived his right to a hearing and accepted the proposed sanction, which terminated on June 16, 2022.
In accordance with CADP rule 10.9.3.1, the two adverse analytical findings are considered a single anti-doping rule violation and the period of ineligibility applies to both samples.
During the sanction period, the athlete, who resides in Lantzville, British Columbia, was ineligible to participate in any capacity with any sport signatory to the CADP, including training with teammates.
In compliance with rule 8.4 of the CADP, the CCES’s file outcome summary can be found in the Canadian Sport Sanction Registry.
The original press release can be found here : https://cces.ca/news/swimming-athlete-suspended-presence-methylphenidate
